Zanubrutinib is currently available as oral capsules and is a precision therapeutic agent. Its core mechanism is to target Bruton's tyrosine kinase, a key therapeutic target, and precisely inhibit the growth signals of abnormal cells, thereby controlling tumor progression.
Drug Name
Generic Name: Zanubrutinib
Active Ingredient
The active ingredient is zanubrutinib, a targeted agent that selectively inhibits Bruton's tyrosine kinase (BTK).
Description
This product is a hard capsule; the contents consist of the active pharmaceutical ingredient (no specific description of the contents' appearance is provided in the original text, and is labeled per the known dosage form).
Indications
This product is indicated for the treatment of adult patients with the following hematologic malignancies:
Mantle cell lymphoma (MCL) who have received at least one prior therapy;
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have received at least one prior therapy.
Strength
Each capsule contains 80 mg of zanubrutinib.
Dosage and Administration
1. Standard Dosage Regimen
Route of administration
Oral administration; swallow the whole capsule with warm water. Do not open, crush or chew the capsule.
Timing of administration
May be taken with or without food, twice daily, with approximately 12 hours between doses.
Standard dose
2 capsules (80 mg per capsule) each time, with a total daily dose of 320 mg.
Duration of treatment
Continue administration until disease progression or unacceptable adverse reactions occur.
2. Dose Modifications
(1) Dose Adjustments for Drug-Drug Interactions
Concomitant use with strong CYP3A inhibitors: Reduce to 1 capsule (80 mg) once daily.
Concomitant use with moderate CYP3A inhibitors: 1 capsule (80 mg) twice daily.
Concomitant use with strong or moderate CYP3A inducers should be avoided (may reduce therapeutic efficacy).
(2) Dose Adjustments for Adverse Reactions
First occurrence of severe adverse reactions (e.g., organ injury, persistent high fever with extreme leukopenia, severe bleeding, failure of hematologic parameters to recover within 10 days): Interrupt treatment. Upon resolution of symptoms to mild or absent, resume the standard dose (2 capsules twice daily).
Second occurrence of the same severe adverse reaction: Upon resolution of symptoms, adjust to 1 capsule (80 mg) twice daily.
Third occurrence of the same severe adverse reaction: Upon resolution of symptoms, reduce to 1 capsule (80 mg) once daily.
Fourth occurrence of severe adverse reactions: Discontinue treatment permanently.
(3) Dose Adjustments for Special Populations
Patients with hepatic impairment: No dose adjustment is required for mild or moderate hepatic impairment; for severe hepatic impairment, 1 capsule (80 mg) twice daily is recommended.
Patients with renal impairment: Standard dosage is applicable for patients with mild, moderate or severe renal impairment; close monitoring for adverse reactions is required in patients with severe renal impairment (eGFR < 30 mL/min) or those undergoing dialysis.
Elderly patients: No dose adjustment is required.
Pediatric patients: No established safety and efficacy data; use must be strictly under medical supervision.
Adverse Reactions
The following adverse reactions may occur during treatment (related to individual constitution and dosage):
Hemorrhage-related events
Epistaxis, gingival bleeding, subcutaneous ecchymosis, etc.
Hematologic system
Decreased red blood cell, white blood cell or platelet counts (cytopenia).
Increased infection risk
Higher incidence of infectious diseases such as upper respiratory tract infection and pneumonia.
Viral reactivation
Reactivation of hepatitis B virus may occur in patients with prior HBV infection.
Risk of second primary malignancies.
Cardiovascular system
Cardiac arrhythmias (e.g., palpitations, chest distress).
Metabolic disorders
Tumor lysis syndrome (caused by rapid death of a large number of tumor cells).
Contraindications
Contraindicated in patients with hypersensitivity to zanubrutinib or any of the excipients in this product.
Precautions for Use
The following populations should use this product only after risk assessment by a physician and under close monitoring:
Pediatric patients (lack of safety data).
Pregnant and lactating women (may affect the fetus/infant).
Patients with severe hepatic or renal insufficiency (may exacerbate organ burden).
Men and women of reproductive potential (must use contraceptive measures).
Use in Special Populations
Patients of reproductive potential
Reliable contraceptive measures must be used during treatment and for at least 2 weeks after discontinuation.
Pregnant women
Avoid use; the drug may affect fetal development.
Lactating women
Avoid use; breastfeeding is prohibited during treatment and for at least 2 weeks after discontinuation.
Elderly patients
No dose adjustment is required; administer per the standard regimen.
Patients with hepatic/renal impairment: Refer to "Dose Adjustments for Special Populations" under Dosage and Administration.
Drug Interactions
CYP3A inhibitors (e.g., certain antibiotics, antifungals)
Slow the metabolism of zanubrutinib and increase plasma concentrations. Dose adjustment is required during concomitant use (refer to Dosage and Administration), otherwise the risk of adverse reactions increases.
CYP3A inducers (e.g., certain antiepileptics, glucocorticoids)
Accelerate the metabolism of zanubrutinib and reduce therapeutic efficacy; concomitant use should be avoided.
P-gp/BCRP substrate drugs (e.g., digoxin, methotrexate)
Zanubrutinib may affect their metabolism, leading to abnormally elevated plasma concentrations. Close monitoring of drug concentrations is required during concomitant use (especially for drugs with a narrow therapeutic window).
Warnings and Precautions
This product must be used under the guidance of a physician experienced in the treatment of hematologic malignancies. Patients must not self-administer or adjust the dosage.
Prior to treatment, inform the physician of past medical history, other concurrent medications, and special physical conditions (e.g., pregnancy planning, pregnancy, abnormal hepatic or renal function).
During long-term treatment, regularly monitor therapeutic efficacy and safety (e.g., complete blood count, hepatic and renal function, blood pressure, heart rate).
If abnormal symptoms occur during treatment (e.g., severe bleeding, persistent high fever, palpitations, dyspnea), contact a physician immediately.
Do not combine with other antineoplastic drugs without a prescription; combination regimens must strictly follow the physician's prescription.
Do not use if the appearance of the product changes (e.g., abnormal color or shape, unusual odor).
Store the product sealed in a dry, cool place out of the reach of children to prevent accidental ingestion.
Missed Dose
If ≤ 6 hours have elapsed since the missed dose: Take the missed dose immediately.
If > 6 hours have elapsed since the missed dose: Skip the missed dose and take the next dose at the scheduled time.
Do not take a double dose to make up for a missed dose.
Overdosage
The specific hazards of zanubrutinib overdosage have not been established. In case of accidental overdosage, closely monitor for adverse symptoms such as dizziness, nausea, and cardiac abnormalities. Regardless of symptom severity, contact the attending physician immediately or go to the emergency department for professional evaluation and appropriate interventions (e.g., gastric lavage).
Pharmacodynamics
Zanubrutinib exerts its antitumor effect by selectively inhibiting Bruton's tyrosine kinase (BTK), a key signaling molecule for B-cell proliferation, thereby blocking the hyperproliferative signals of abnormal B cells and precisely controlling tumor progression.
Clinical Application Notes
This product does not directly alleviate tumor-related symptoms, but improves symptoms indirectly by inhibiting tumor progression. Potential ameliorated manifestations include lymphadenopathy, persistent fatigue, unexplained fever, night sweats, unintentional weight loss, splenomegaly (distension in the left upper abdomen), easy bruising or prolonged bleeding.
